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Abstract 
Novel peptides with antihypertensive effects in SHR rats have previously been identified in 
lactoferrin (LF) hydrolysates. To investigate their in vivo antihypertensive mechanism, we have 
assessed the blood pressure lowering effects of two of these LF-derived peptides (RPYL and 
DPYKLRP) in Wistar rats subjected to either angiotensin I- or angiotensin II-induced 
hypertension. Blood pressure was measured by the tail-cuff method, hypertension was 
induced by subcutaneous infusion of angiotensins, and then captopril, valsartan or LF-derived 
peptides orally administered. Angiotensin I- and angiotensin II-induced hypertension were 
reversed by captopril and valsartan, respectively. RPYL and DPYKLRP reversed angiotensin I-
induced hypertension, while DPYKLRP but not RPYL produced a modest reversion of 
angiotensin II-elicited hypertension. Neither RPYL nor DPYKLRP modified normotension. Thus, 
in vivo ACE inhibition is involved in the antihypertensive effects of LF-derived peptides like 
RPYL and DPYKLRP, while inhibition of AT1 receptor-mediated vasoconstriction plays a less 
relevant role.
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1. Introduction 
Hypertension is an important modifiable risk factor for cardiovascular disease, which 
its management includes not only pharmacological treatment but also lifestyle changes like 
physical activity and dietary habits (Ruilope, 2011). The increasing perception about the 
relationship between food and health is fostering the development of functional foods 
providing health benefits beyond nutrition (Roberfroid, 2002). Some dietary proteins contain 
embedded peptides that once released behave as bioactive peptides with different health-
promoting properties including blood pressure lowering effects (Hartmann & Meisel, 2007). 
The renin angiotensin system (RAS), a key player in blood pressure and fluid balance 
regulation, is one of the main targets for the treatment of hypertension. Its inhibition at three 
possible levels, angiotensin-converting enzyme (ACE), upstream renin activity, or downstream 
angiotensin receptors, is the pharmacological basis for commonly used antihypertensive drugs 
(Fragasso et al., 2012). ACE inhibition is also the most aimed target for antihypertensive food-
derived peptides developed as an alternative to drugs (Hong et al., 2008). Although different 
animal and plant proteins have been used, milk is the main source of antihypertensive ACE-
inhibitory peptides reported to date (-Ledesma, Contreras, & Recio, 2011; 
Korhonen, 2009). 
Despite numerous efforts, the in vivo mechanism underlying vasoactive and blood 
pressure lowering effects of antihypertensive food-derived peptides has not yet been fully 
established, which may hamper their use as bioactive ingredients in functional foods. A recent 
Scientific Opinion  of the European Food Safety Authority on the substantiation of health 
claims related to isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) and 
maintenance of normal blood pressure, stated that there was no convincing evidence for a 
mechanism by which these widely studied bioactive peptides could exert the claimed effect 
(EFSA Panel on Dietetic Products, Nutrition and Allergies, 2012). Beyond in vivo ACE inhibition 
reported for some peptides and hydrolysates (Jäkälä, Hakala , Turpeinen , Korpela, & 
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Vapaatalo, 2009; Lu et al., 2011; Wang et al., 2012; Yang, Yang, Chen, Tzeng, & Han, 2004) 
antihypertensive effects could be mediated by their interaction with other RAS steps and 
related pathways in the vascular system, potentially contributing to blood pressure reduction 
(Udenigwe & Mohan, 2014).  
In previous studies, antihypertensive properties of peptides derived from bovine 
lactoferrin (LF), a well-characterized protein of milk whey, were shown in spontaneously 
hypertensive rats (SHR) (Ruiz-Giménez et al., 2010). Focusing on the RAS system, we have 
reported in vitro ACE inhibition by a LF pepsin hydrolysate (named pepsin LFH <3kDa) and its 
antihypertensive effect in SHR rats after acute oral administration (Ruiz-Giménez et al., 2012). 
Moreover, chronic oral administration of pepsin LFH <3kDa to SHR rats resulted in reductions 
of  hypertension progression, circulating ACE activity, angiotensin II and aldosterone levels, as 
well as a compensatory increase of renin activity (Fernández-Musoles, Manzanares, Burguete, 
Alborch, & Salom, 2013a). Recently, we have reported that in vitro inhibition of ACE activity by 
pepsin LFH <3kDa also occurred in cultured human endothelial cells (García-Tejedor et al., 
2015). On the other hand, dairy yeasts (Debaryomyces hansenii, Kluyveromyces lactis and K. 
marxianus) produced LF-derived antihypertensive hydrolysates. Among them, the hydrolysate 
produced by a particular strain of Kluyveromyces marxianus (named Km2 pLFH) showed the 
highest in vitro ACE inhibition and in vivo blood pressure reduction in SHR rats (García-Tejedor, 
Padilla, Salom, Belloch, & Manzanares, 2013). 
Novel bioactive peptides have been identified in LF hydrolysates obtained by 
enzymatic proteolysis or yeast fermentation, and some of them have been particularly 
characterized. Among peptides identified in pepsin LFH <3kDa, the tetrapeptide RPYL 
produced in vitro ACE inhibition, ex vivo inhibition of ACE-dependent vasoconstriction induced 
by angiotensin I and in vivo reduction of systolic blood pressure in SHR rats (Ruiz-Giménez et 
al., 2012). Moreover, RPYL also produced ex vivo inhibition of angiotensin II-elicited 
vasoconstriction by blocking angiotensin AT1 receptors (Fernández-Musoles et al., 2014). On 
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the other hand, among peptides identified in Km2 pLFH, the heptapeptide DPYKLRP produced 
in vitro ACE inhibition and in vivo decrease of systolic blood pressure in SHR rats. Moreover, 
antihypertensive effects in SHR rats were accompanied by reductions in circulating ACE activity 
and angiotensin II level (García-Tejedor et al., 2014). Further in vivo studies to elucidate the 
mechanism of action of milk protein-derived antihypertensive peptides are still necessary to 
develop dairy functional foods. In order to gain insight into the in vivo antihypertensive 
mechanism of the LF-derived peptides RPYL and DPYKLRP, we have assessed their blood 
pressure lowering effects in Wistar rats subjected to either angiotensin I- or angiotensin II-
induced hypertension. 
2. Materials and methods 
2.1.Materials 
Peptides (RPYL and DPYKLRP) were ordered from GenScript Corp. (Piscataway, NJ, 
USA) wherein they were synthesized by solid phase methods using N-(9-fluorenyl) 
methoxycarbonyl (Fmoc) chemistry. Peptide purities of supplied batches were 99.7% for RPYL 
and 96.9% for DPYKLRP. Angiotensin I, angiotensin II, captopril and valsartan were purchased 
from Sigma-Aldrich Química (Tres Cantos, Madrid, Spain). ALZET Osmotic Pumps (model 2ML4)
were purchased from Charles River Laboratories (Barcelona, Spain). Diazepam and ketamine 
were purchased from Roche Farma (Madrid, Spain) and Parke-Davis (Alcobendas, Madrid, 
Spain), respectively.
2.2.Animal welfare 
Experimental procedures were conducted in accordance with the Spanish legislation 
o ‘Potctio of Aimals us fo Expimtal a oth Scitific Puposs’ a the study 
was appov by th ‘Ethics Committ fo Aimal Wlfa’ of th ospital La F to b cai 
out in its accredited animal research facility. 
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Ten male Wistar rats (200-225 g) were supplied by Charles River Laboratories 
(Barcelona, Spain). Rats were housed in temperature-controlled rooms (23 °C) with 12 h 
light/dark cycles, and consumed tap water and standard diet ad libitum. A two-week period of 
acclimatization was allowed to recover from the stress associated with transportation 
(Obernier & Baldwin, 2006). To minimize the impact of light cycle and feeding on circadian 
rhythms of blood pressure (van den Buuse, 1999), the experiments always started at the same 
time in the morning (9:00 a.m.) in fasted rats. 
2.3.Blood pressure measurement 
 Indirect measurement of systolic blood pressure (SBP) was carried out in awake 
restrained rats by the noninvasive tail-cuff method using computer-assisted Non-Invasive 
Blood Pressure equipment (LE5001 unit with LE5160R cuff and transducer, Panlab Harvard 
Apparatus, Cornellá, Barcelona, Spain). This method has been validated with direct intra-
arterial measurements (Ibrahim, Berk, & Hughes, 2006). Before the measurements, rats were 
kept at 37 °C during 15 min to make the pulsations of the tail artery detectable. Each value of 
SBP was obtained by averaging at least three consecutive and successful measurements 
without disturbance of the signal. Changes in SBP were calculated as the absolute difference 
(in mm Hg) with respect to the basal values of measurements obtained just before starting the 
treatments. 
2.4.Hypertension induction 
 Rats were anaesthetized by intraperitoneal injection of 5 mg/kg diazepam and 100 
mg/kg ketamine. An ALZET Osmotic Pump (model 2ML4) was surgically implanted 
subcutaneously on the back, between and slightly posterior to the scapulae. The osmotic 
pump was filled with either angiotensin I (11.1 mg/2 mL 0.1 M acetic acid) or angiotensin II 
(11.1 mg/2 mL distilled water), and delivered continuously for 4 weeks at a rate of 2.5 µL/hr, 
that is around 1 mg angiotensin/kg/day. The SBP was measured before angiotensin infusion 
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(zero time) and twice a week during 24 days of infusion. Physiological saline was infused as 
negative control. 
2.5.Assay of lactoferrin-derived peptides 
 Peptides (RPYL or DPYKLRP, 10 mg/kg) were orally administered by gastric intubation 
in 650 μL of physiological saline. The SBP was measured before peptide intake (zero time) and 
1.5, 3, and 24 h after intake. In assays on angiotensin I-induced hypertension captopril (10 
mg/kg) served as positive control, whereas in assays on angiotensin II-induced hypertension 
valsartan (10 mg/kg) was the positive control. The vehicles for peptides and captopril
(physiological saline) and for valsartan (dimethyl sulfoxide, DMSO) were assayed as negative 
controls.
2.6.Data analysis and statistics 
Values are expressed as the mean ± SEM. Upai Stut’s t tst was us to assss 
differences between two groups. Analysis of variance (ANOVA) followed by Student-Newman-
Kuls tst o Dutt’s test was used for multiple comparisons among more than two groups. 
P values <0.05 were considered significant. 
3. Results 
3.1.Angiotensin I and angiotensin II induced blood pressure increases
 Average basal SBP in Wistar rats was 119 ± 2 mm Hg (n = 10). Continuous 
subcutaneous infusion of angiotensin I (1 mg/kg/day) induced increase in SBP (Fig. 1), which 
became significantly higher than SBP in saline-infused control rats from day 3. Steady-state 
SBP levels were attained after 17 days (151 ± 7 mm Hg, n = 4 in angiotensin I vs 123 ± 1 mm Hg, 
n = 3 in saline control at this time point). Infusion of angiotensin II (1 mg/kg/day) induced 
increase in SBP (Fig. 1), which became significantly higher than SBP in both saline control- and 
angiotensin I-infused rats from day 3. Steady-state SBP levels were also attained after 17 days 
(189 ± 1 mm Hg, n = 3 in angiotensin II vs 123 ± 1 mm Hg, n = 3 in saline control at this time 
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point). SBP remained at hypertensive levels in both angiotensin I- and angiotensin II-infused 
rats until the end of infusion, at day 28, and returned to normotensive  values upon osmotic 
pump withdrawal (126 ± 1 mm Hg, n = 4; and 123 ± 1 mmHg, n = 3, respectively). 
3.2.Lactoferrin-derived peptides reversed angiotensin I-induced hypertension 
 In angiotensin I-induced hypertensive rats (155 ± 2 mm Hg, n = 26), oral boluses (10 
mg/kg) of RPYL or to a higher extent DPYKLRP induced transient decreases in SBP. Values of 
SBP were maximally reduced at 1.5 h after peptide intake, remained significantly reduced at 3 
h, and returned to basal values at 24 h (Fig. 2). For comparison, oral captopril (10 mg/kg) 
elicited decrease in SBP which was maximal at 1.5 h after intake and remained significant even 
at 24 h (Fig. 2). Decreases in SBP induced by the two peptides and captopril at 1.5 h were 
significantly different among them: RPYL < DPYKLRP < captopril (P<0.05, Student-Newman-
Keuls test). 
3.3.Heptapeptide DPYKLRP but not tetrapeptide RPYL reversed angiotensin II-induced 
hypertension 
 With regard to angiotensin II-induced hypertensive rats (183 ± 2 mm Hg, n = 34), oral 
boluses (10 mg/kg) of DPYKLRP but not RPYL induced transient decrease in SBP. Values of SBP 
were significantly reduced only at 1.5 h after DPYKLRP intake, and returned to basal values at 
24 h (Fig. 3). For comparison, oral valsartan (10 mg/kg) elicited decrease in SBP (when 
compared to DMSO control) which was maximal at 1.5 after intake and remained significant 
even at 24 h (Fig. 3). In contrast, captopril (10 mg/kg) did not significantly modify SBP level in 
angiotensin II-induced hypertensive rats (Fig. 3). 
3.4.Lactoferrin-derived peptides did not modify normotensive blood pressure levels 
 Neither lactoferrin-derived peptides (RPYL and DPYKLRP) nor drugs (captopril and 
valsartan), orally administered at the same dose used in hypertensive rats (10 mg/kg), 
produced significant changes on normortensive SBP levels in Wistar rats (Table 1). 
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4. Discussion 
 We have found that both the tetrapeptide RPYL and to a higher extent the 
heptapeptide DPYKLRP reverse angiotensin I-induced hypertension when orally administered 
to Wistar rats. Moreover, DPYKLRP also produces a modest reversion of angiotensin II-elicited 
hypertension. Of note, neither RPYL nor DPYKLRP modified arterial blood pressure in 
normotensive rats. We and others have extensively used the SHR rat as hypertension model to 
assess the antihypertensive effects of food protein-derived bioactive peptides (Martínez-
Maqueda, Miralles, Recio, & Hernández-Ledesma, 2012). However, this approach does not 
allow knowing the in vivo antihypertensive mechanism, unless for example blood components 
of the RAS are determined (Fernández-Musoles et al., 2013a; Lu et al., 2011). Alternatively, 
angiotensin I- or angiotensin II-induced hypertension rat models have been used to gain insight 
into the in vivo antihypertensive mechanism of diverse non-drug natural products (Liu et al., 
2003; Prasad, 2013; Waghulde, Mohan, Kasture, & Balaraman, 2010). In the present study, we 
have combined both angiotensin I- and angiotensin II-induced hypertension in order to 
discriminate between effects on ACE activity and effects on downstream activation of 
angiotensin AT1 receptors of LF-derived peptides. 
 Antihypertensive effects in SHR rats have previously been shown for both RPYL (Ruiz-
Giménez et al., 2012) and DPYKLRP (García-Tejedor et al., 2014). In the present study, both 
RPYL and DPYKLRP reversed angiotensin I-induced hypertension in Wistar rats. Like in SHR rats, 
the magnitude and duration of the antihypertensive effect was higher for DPYKLRP than for 
RPYL on angiotensin I-induced hypertension. We used the ACE inhibitor drug captopril as a 
positive control, which showed antihypertensive effects. It has been previously reported that 
captopril, at the same dose used in our study, produces almost complete inhibition of plasma 
ACE activity and attenuation of pressor responses to angiotensin I (Levens, Peach, Vaughan, 
Weed, & Carey, 1981). Therefore, angiotensin I-induced hypertension is a suitable model to 
assess in vivo ACE inhibition, and then our results support ACE inhibition as antihypertensive 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
10 
mechanism for the LF-derived peptides RPYL and DPYKLRP. Few studies have previously 
assessed in vivo ACE inhibitor effect of milk-derived peptides by means of angiotensin I 
administration. Milks fermented using two strains of Lactobacillus helveticus produced 
inhibition of angiotensin I-elicited acute pressor responses in anaesthetized Sprague Dawley 
rats (Fuglsang, Rattray, Nilsson, & Nyborg, 2003b). In contrast, milk-derived short peptides 
produced no effect or very moderate inhibition of these angiotensin I-elicited pressor 
responses (Fuglsang, Nilsson, & Nyborg, 2003a) On the other hand, a peptide concentrate 
obtained from hydrolysis of bovine whey brought about by Cynara cardunculus cardosins 
(PepC) and an α-lactalbumin-derived peptide identified in PepC (KGYGGVSLPEW) produced 
inhibition of angiotensin I-elicited acute pressor responses in anaesthetized SHR rats (Tavares, 
Sevilla, Montero, Carrón, & Malcata, 2012). In contrast to these previous studies in 
anesthetized rats, our in vivo assays were carried out in awake, shortly restrained rats, with a 
steady-state level of angiotensin I-induced hypertension, which resembles established 
hypertension in SHR rats. 
 We have previously shown that antihypertensive LF-derived peptides induce some 
changes in blood RAS components of SHR rats. On one hand, the pepsin LFH <3kDa hydrolysate 
in which RPYL was identified induced reductions of circulating ACE activity, angiotensin II and 
aldosterone levels, as well as a compensatory increase of renin activity (Fernández-Musoles et 
al., 2013a). On the other hand, DPYKLRP also induced reductions of circulating ACE activity and 
angiotensin II level (García-Tejedor et al., 2014). Thus, reversions of angiotensin I-induced 
hypertension observed in the present study are in line with reported changes in blood RAS 
components, and all together consistently support ACE inhibition as in vivo antihypertensive 
mechanism for LF-derived peptides like RPYL and DPYKLRP. 
 As for alternative antihypertensive mechanisms beyond ACE inhibition, our prior ex 
vivo study carried out in isolated arteries showed inhibitory effects of pepsin LFH <3kDa 
hydrolysate and several LF-derived peptides including RPYL on angiotensin II-induced 
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vasoconstriction because of an angiotensin AT1 receptor blocking effect (Fernández-Musoles et 
al., 2014). This prompted us to assess in the present study the in vivo effects of the LF-derived 
peptides RPYL and DPYKLRP on activation of angiotensin AT1 receptors. Our results showed 
that DPYKLRP produced a modest reversion of angiotensin II-elicited hypertension. We used 
the angiotensin AT1 receptor antagonist drug valsartan as positive control, which showed 
strong antihypertensive effects, as previously reported (Kobayashi, Imanishi, & Akasaka, 2006). 
In contrast, the ACE inhibitor drug captopril did not modify angiotensin II-elicited 
hypertension, as expected (Textor, Brunner, & Gavras, 1981). Therefore, angiotensin II-induced 
hypertension is a proper model to assess in vivo inhibition of angiotensin AT1 receptors, and 
then our results suggest a less relevant role for inhibitory effect on vasoactive responses 
mediated by angiotensin AT1 receptors as antihypertensive mechanism for the assayed LF-
derived peptides. The fact that ex vivo angiotensin AT1 receptor blocking effect of RPYL was 
not confirmed in the present in vivo study points to oral peptide bioavailability and raises the 
question about the final active form of food derived antihypertensive peptides (-
Ledesma et al., 2011). As far as we know, no study has previously assessed in vivo effects of 
milk-derived peptides on vasoactive responses mediated by angiotensin AT1 receptors by 
means of angiotensin II administration. 
 Finally, beyond their effects on different steps of the RAS system, we have reported 
that some LF-derived peptides different to those studied here may act as dual vasopeptidase 
inhibitors since, in addition to ACE, they can also produce in vitro inhibition of endothelin-
converting enzyme (ECE) activity and ex vivo inhibition of ECE-dependent vasoconstriction 
(Fernández-Musoles et al., 2010, 2013b). Since ECE is a key enzyme of the endothelin system, 
which is also involved in vascular tone and blood pressure regulation, in vivo participation of 
this inhibitory mechanism in the antihypertensive effects of LF-derived peptides like RPYL and 
DPYKLRP deserves further research. 
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5. Conclusions 
 Reversion of angiotensin I-induced hypertension by RPYL and DPYKLRP point to in vivo
ACE inhibition as a mechanism involved at least in part in the antihypertensive effects of these 
LF-derived peptides. On the other hand, slight reversion of angiotensin II-induced hypertension 
by DPYKLRP, and no effect at all of RPYL, suggests a less relevant role for an inhibitory effect on 
vasoactive responses mediated by angiotensin AT1 receptors as antihypertensive mechanism 
for these bioactive peptides. Finally, it should be also noted that the effect of RPYL and 
DPYKLRP were specific to the angiotensin-induced hypertensive states, because these peptides 
did not modify the arterial blood pressure of normotensive rats. Individual peptides could be 
applied as nutraceuticals in health-promoting functional foods for the treatment of 
hypertension. 
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Figure legeds 
Fig. 1 - Time course of systolic blood pressure (SBP) during subcutaneuous continuous infusion 
(1 mg/kg/day) of angiotensin I and angiotensin II to Wistar rats by means of an osmotic pump. 
Physiological saline was infused as negative control. SBP is expressed in mm Hg and values are 
mean ± SEM from 3-4 determinations. *P<0.05 versus saline control, **P<0.01 versus saline 
control, and ##P<0.01 versus angiotensin I (one-way ANOVA followed by Student-Newman-
Keuls tests). 
Fig. 2 - Time course of systolic blood pressure (SBP) after oral boluses (10 mg/kg) of lactoferrin-
derived peptides RPYL and DPYKLRP administered to angiotensin I-induced hypertensive 
Wistar rats. Captopril was administered as positive control, whereas the vehicle for peptides 
and captopril (physiological saline) served as negative control. SBP chag (∆SBP) is expressed 
in absolute values (mm Hg) and data are mean ± SEM from 4-8 determinations. *P<0.05 versus 
saline control, **P<0.01 versus saline control (one-way ANOVA followed by Dutt’s tsts). 
Fig. 3 - Time course of systolic blood pressure (SBP) after oral boluses (10 mg/kg) of lactoferrin-
derived peptides RPYL and DPYKLRP administered to angiotensin II-induced hypertensive 
Wistar rats. Valsartan was administered as positive control, whereas captopril served to check 
for angiotensin converting enzyme inhibition. The vehicles for peptides and captopril 
(physiological saline) and for valsartan (dimethyl sulfoxide, DMSO) were administered as 
negative controls. SBP chag (∆SBP) is expressed in absolute values (mm Hg) and data are 
mean ± SEM from 4-6 determinations. **P<0.01 versus saline control (one-way ANOVA 
follow by Dutt’s tsts), ##P<0.01 versus DMSO control (upai Stut’s t tst). 
Table 1. Time course of systolic blood pressure (SBP) in normotensive Wistar rats after oral 
administration of lactoferrin-derived peptides (RPYL and DPYKLRP), captopril and valsartan.  
Time (h)
0 1.5 3 24 
Salinea control 124 ± 1 (6) 125 ± 1 (6) 126 ± 1 (6) 125 ± 2 (6)
Captopril (10 mg/kg) 127 ± 2 (5) 126 ± 2 (5) 125 ± 1 (5) 124 ± 2 (5)
RPYL (10 mg/kg) 126 ± 3 (5) 125 ± 2 (5) 129 ± 2 (5) 127 ± 3 (4)
DPYKLRP (10 mg/kg) 124 ± 2 (6) 125 ± 1 (6) 125 ± 1 (6) 126 ± 1 (6)
DMSOb control 127 ± 2 (6) 128 ± 2 (5) 127 ± 1 (5) 127 ± 2 (5)
Valsartan (10 mg/kg) 125 ± 3 (3) 127 ± 1 (3) 124 ± 2 (3) 124 ± 1 (3)
SBP is expressed in mm Hg and values are mean ± SEM from (n) determinations. 
aVehicle for captopril, RPYL and DPYKLRP. 
bDimethyl sulfoxide, vehicle for valsartan. 
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